Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 2 140 GBX 0.47%
Market Cap: 4.7B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Relative Value

The Relative Value of one HIK stock under the Base Case scenario is 7 253.15 GBX. Compared to the current market price of 2 140 GBX, Hikma Pharmaceuticals PLC is Undervalued by 70%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HIK Relative Value
Base Case
7 253.15 GBX
Undervaluation 70%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
44
vs Industry
54
Median 3Y
1.9
Median 5Y
2
Industry
2.5
Forward
0
vs History
38
vs Industry
30
Median 3Y
19.7
Median 5Y
16.6
Industry
21.3
Forward
0.1
vs History
28
vs Industry
37
Median 3Y
8.9
Median 5Y
9.7
Industry
16.7
vs History
50
vs Industry
25
Median 3Y
19.4
Median 5Y
19.4
Industry
24.7
vs History
31
vs Industry
30
Median 3Y
2.4
Median 5Y
2.5
Industry
2.1
vs History
76
vs Industry
7
Median 3Y
31.3
Median 5Y
26
Industry
2.6
Forward
0.2
vs History
76
vs Industry
3
Median 3Y
65.5
Median 5Y
50.2
Industry
5.1
vs History
76
vs Industry
2
Median 3Y
102.3
Median 5Y
95.7
Industry
12.8
Forward
0.6
vs History
76
vs Industry
3
Median 3Y
151.7
Median 5Y
115.5
Industry
16.3
Forward
0.7
vs History
66
vs Industry
3
Median 3Y
160.3
Median 5Y
148.2
Industry
14.9
vs History
66
vs Industry
2
Median 3Y
247
Median 5Y
247
Industry
18.2
vs History
76
vs Industry
5
Median 3Y
23.2
Median 5Y
17.3
Industry
1.9

Multiples Across Competitors

HIK Competitors Multiples
Hikma Pharmaceuticals PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Hikma Pharmaceuticals PLC
LSE:HIK
4.7B GBP 2 17.8 65.9 83.5
US
Eli Lilly and Co
NYSE:LLY
699.1B USD 14.3 62.9 33.9 37
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.4B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 6.8 19.7 13.7 15.8
CH
Roche Holding AG
SIX:ROG
211.1B CHF 3.5 25.5 9.6 11.2
CH
Novartis AG
SIX:NOVN
186.4B CHF 4.3 17.6 10.4 13.9
UK
AstraZeneca PLC
LSE:AZN
164.9B GBP 4 28.6 130.9 197.4
US
Merck & Co Inc
NYSE:MRK
193.3B USD 3 11.1 8.3 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
133.5B USD 2.1 16.9 7.3 10.3
P/E Multiple
Earnings Growth PEG
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average P/E: 24.2
17.8
20%
0.9
US
Eli Lilly and Co
NYSE:LLY
62.9
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.7
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.5
32%
0.8
CH
Novartis AG
SIX:NOVN
17.6
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.6
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.1
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.9
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average EV/EBITDA: 400
65.9
9%
7.3
US
Eli Lilly and Co
NYSE:LLY
33.9
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.6
5%
1.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.9
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.3
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average EV/EBIT: 1 704.8
83.5
12%
7
US
Eli Lilly and Co
NYSE:LLY
37
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
CH
Novartis AG
SIX:NOVN
13.9
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.4
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.1
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1